Health and Me

Rachel V Thomas

US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD

The US Food and Drug Administration (FDA) has announced to hold a public hearing on the potential therapeutic use of psychedelic drugs, as the Donald Trump administration pushes to accelerate research and development of these treatments for serious mental illnesses. 

The hearing, it said, will examine their potential use in supervised and supportive settings, including patient safety, provider training, access and data collection. 

In a statement, the FDA said it is collaborating with federal partners and holding “this public hearing to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a <span>psychedelic drug</span> substance in supervised and supportive settings”. 

<h2>What Will The FDA Hearing Discuss? </h2>

<strong>Also read: </strong><a href="https://www.healthandme.com/health-news/ibogaine-why-trump-is-pushing-us-fda-to-fast-track-this-psychedelic-article-154177034" data-type="tilCustomLink">Ibogaine: Why Donald Trump Is Pushing US FDA To Fast-track This Psychedelic</a>

The hearing will focus on what would be needed for the potential therapeutic use of psychedelic drugs in supervised and supportive settings. 

<ul><li>Provider training and credentialing </li></ul><ul><li>Patient safety </li></ul><ul><li>Access to treatment </li></ul><ul><li>Data collection and standardization </li></ul>

Emerging research shows <span>psychedelics</span> can help improve mental health, especially in conditions where traditional treatment approaches have not been useful. However, these drugs also come with several health risks that cannot be overlooked.

The hearing is part of broader US efforts to increase clinical trial participation, data sharing and real-world evidence on psychedelic drugs. The FDA hearing does not amount to approval of psychedelic treatments. Instead, it could help shape how the US approaches their potential future use in medical care.  

<h2>What Does This Mean For <span rel="noindex"><a href="https://www.healthandme.com/health/depression">Depression</a></span> And <span rel="noindex">PTSD</span>? </h2>

The FDA has already taken steps to speed up the development of psychedelic treatments for mental health conditions. 

In April 2026, the agency issued national priority vouchers to companies studying psilocybin for treatment-resistant depression (TRD), psilocybin for major depressive disorder (MDD), and methylone for post-traumatic stress disorder (PTSD). 

The FDA has also granted Breakthrough Therapy designation to psychedelic drug programs involving MDMA for PTSD and psilocybin for TRD and MDD. 

Research over the past decade has suggested that MDMA-assisted therapy may help reduce PTSD symptoms, while psilocybin-assisted therapy has shown promise for treatment-resistant depression in clinical studies. 

For people who do not get lasting relief from existing treatments such as antidepressants and psychotherapy, psychedelic-assisted therapy could potentially offer another treatment option. 

However, these designations and regulatory steps do not mean that these drugs have been approved as safe or effective treatments. Neither a national priority voucher nor Breakthrough Therapy designation is a substitute for FDA marketing approval. 

Read More: <a href="https://www.healthandme.com/health-news/psychedelic-compound-found-in-magic-mushrooms-may-help-prevent-painful-chemotherapy-side-effects-study-finds-article-156097745" data-type="tilCustomLink">Psychedelic Compound Found In 'Magic Mushrooms' May Help Prevent Painful Chemotherapy Side Effects, Study Finds</a>

 <h2>Why Is The US Accelerating Psychedelic Research? </h2>

The push has expanded beyond the FDA. In 2026, the White House, Congress and the Department of Veterans Affairs (VA) have also become involved in efforts to accelerate research into psychedelic treatments, including psilocybin, MDMA and ibogaine. 

The US Department of Health and Human Services (HHS) has partnered with the VA to accelerate the development of psychedelic-assisted therapies for veterans with conditions including PTSD, depression and traumatic brain injury. 

Separately, a bipartisan group of lawmakers introduced a bill that would require the US Department of Defense to evaluate whether ongoing psychedelic research, particularly involving psilocybin, could benefit active-duty service members and veterans transitioning to civilian life.

Health Conditions A-Z

health

us-fda-to-hold-psychedelic-drug-hearing-amid-trump-push-what-it-means-for-depression-ptsd

Psychedelic Drug

Psychedelics

FDA To Hold Psychedelic Drug Hearing

Depression

PTSD

Psychedelics for mental health

1370-mpox-cases-7-deaths-reported-in-july-who-says-risk-remains-moderate

1,370 Mpox Cases, 7 Deaths Reported In July: WHO Says Risk Remains Moderate

lung-cancer-2-gsk-biontech-drugs-show-survival-94-response

Lung Cancer: 2 Drugs From GSK, BioNTech Show Improved Survival, 94% Response

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The US Food and Drug Administration (FDA) has announced to hold a public hearing on the potential therapeutic use of psychedelic drugs, as the Donald Trump administration pushes to accelerate research and development of these treatments for serious mental illnesses. The hearing, it said, will examine their potential use in supervised and supportive settings, including patient safety, provider training, access and data collection. In a statement, the FDA said it is collaborating with federal partners and holding “this public hearing to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings”. What Will The FDA Hearing Discuss? Also read: Ibogaine: Why Donald Trump Is Pushing US FDA To Fast-track This PsychedelicThe hearing will focus on what would be needed for the potential therapeutic use of psychedelic drugs in supervised and supportive settings. Key areas include: Provider training and credentialing Patient safety Access to treatment Data collection and standardization Emerging research shows psychedelics can help improve mental health, especially in conditions where traditional treatment approaches have not been useful. However, these drugs also come with several health risks that cannot be overlooked.The hearing is part of broader US efforts to increase clinical trial participation, data sharing and real-world evidence on psychedelic drugs. The FDA hearing does not amount to approval of psychedelic treatments. Instead, it could help shape how the US approaches their potential future use in medical care.  What Does This Mean For Depression And PTSD? The FDA has already taken steps to speed up the development of psychedelic treatments for mental health conditions. In April 2026, the agency issued national priority vouchers to companies studying psilocybin for treatment-resistant depression (TRD), psilocybin for major depressive disorder (MDD), and methylone for post-traumatic stress disorder (PTSD). The FDA has also granted Breakthrough Therapy designation to psychedelic drug programs involving MDMA for PTSD and psilocybin for TRD and MDD. Research over the past decade has suggested that MDMA-assisted therapy may help reduce PTSD symptoms, while psilocybin-assisted therapy has shown promise for treatment-resistant depression in clinical studies. For people who do not get lasting relief from existing treatments such as antidepressants and psychotherapy, psychedelic-assisted therapy could potentially offer another treatment option. However, these designations and regulatory steps do not mean that these drugs have been approved as safe or effective treatments. Neither a national priority voucher nor Breakthrough Therapy designation is a substitute for FDA marketing approval. Read More: Psychedelic Compound Found In 'Magic Mushrooms' May Help Prevent Painful Chemotherapy Side Effects, Study Finds Why Is The US Accelerating Psychedelic Research? The push has expanded beyond the FDA. In 2026, the White House, Congress and the Department of Veterans Affairs (VA) have also become involved in efforts to accelerate research into psychedelic treatments, including psilocybin, MDMA and ibogaine. The US Department of Health and Human Services (HHS) has partnered with the VA to accelerate the development of psychedelic-assisted therapies for veterans with conditions including PTSD, depression and traumatic brain injury. Separately, a bipartisan group of lawmakers introduced a bill that would require the US Department of Defense to evaluate whether ongoing psychedelic research, particularly involving psilocybin, could benefit active-duty service members and veterans transitioning to civilian life.

us fda to hold psychedelic drug hearing amid trump push: what it means for depression, ptsd

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD

1,370 Mpox Cases, 7 Deaths Reported In July: WHO Says Risk Remains Moderate

Lung Cancer: 2 Drugs From GSK, BioNTech Show Improved Survival, 94% Response

US Measles Outbreak: Can Vaccinated People Still Get Infected?

Health Conditions A-Z

US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD

1,370 Mpox Cases, 7 Deaths Reported In July: WHO Says Risk Remains Moderate

Lung Cancer: 2 Drugs From GSK, BioNTech Show Improved Survival, 94% Response